Pfizer shares dip after CFO departure raises new questions about 2026 outlook
Pfizer dropped 2.7% to $25.21 Thursday, closing out a short week lower after its CFO said he is leaving. The news raised questions about Pfizer’s 2026 outlook and its post-pandemic turnaround. U.S. markets shut Friday for Juneteenth. That’s what investors head into next week with. Pfizer isn’t only swapping finance chiefs; the company is making the change as it works to prove its deals, cuts, and fresh drugs are enough to offset weaker COVID vaccine and antiviral demand.